EASL Video Podcasts

EASL Studio Podcast: Does it really matter whether we call it ACLF or acute decompensation?

This episode questions whether assigning the label “ACLF” to a deteriorating patient truly alters clinical decisions, or if focusing on the specifics of organ failure and reversibility is more useful. Experts debate the real-world utility of prognostic scores, the clarity (or confusion) created by multiple definitions, and whether the ACLF concept drives urgency, facilitates transplant access, or improves outcomes. A thought-provoking look at where terminology meets bedside care.
Moderator: Tom Marjot 
Speakers: Paolo Angeli and Julia Wendon
This EASL Studio is supported by GENFIT. EASL has received no input from GENFIT with regards to the content of this programme. 
All EASL Studio Podcasts are available on EASL Campus.
Click here to see all EASL Video Podcasts on Apple Podcasts.

EASL Studio Podcast The Clinical Blind Spot: Are We Neglecting Alcohol?

This EASL Studio explores the discrepancy between the huge burden of patients hospitalised with, and dying from, alcohol-related liver disease (ALD) or MetALD, versus the same disease’s near non-existence from population data. The panel will discuss whether current classification systems (heavily favoring metabolic causes) misrepresent the true burden of ALD and MetALD, and what clinicians can do to better map the role of alcohol in liver patients.
Moderator: Maja Thiele
Speakers: Brian Lee, Mzamo Mbelle, Elisa Pose
All EASL Studio Podcasts are available on EASL Campus.
Click here to see all EASL Video Podcasts on Apple Podcasts.

EASL Studio Podcast: Hepatitis C, Re-infection or Failure of Treatment in People Engaging in High Risk Practices – Do These Labels Matter in 2025?

What do we call it when someone with high-risk practices becomes viraemic again after treatment? In this episode, experts discuss the challenges of managing Hepatitis C in people who inject drugs (PWID) and other high-risk groups. Topics include SVR confirmation rates, DAA prescribing practices, acute vs. chronic infection, and real-world reinfection data. Are traditional labels still meaningful or do we need new frameworks for 2025?
Moderator: Ahmed Elsharkawy
Speakers: Ashley Brown, Tatyana Kushner and Sabela Lens
This EASL Studio is supported by AbbVie. EASL has received no input from AbbVie with regards to the content of this programme.
All EASL Studio Podcasts are available on EASL Campus.
Click here to see all EASL Video Podcasts on Apple Podcasts.

EASL Studio Podcast: What Matters Most? The questions every hepatologist should ask their patients

In hepatology, effective care goes beyond diagnostics and treatment. This episode explores the crucial questions hepatologists should ask to truly understand their patients’ needs, values, and priorities. By focusing on communication and patient-centred care, our experts highlight how listening carefully can improve adherence, enhance quality of life, and ultimately lead to better outcomes.
Moderator: Pierre-Emmanuel Rautou
Speakers: Agnès Dumas, Maria Hjorth, José Willemse, Zobair Younossi
All EASL Studio Podcasts are available on EASL Campus.
Click here to see all EASL Video Podcasts on Apple Podcasts.

EASL DeepDive: Diagnosis, non-invasive screening and risk stratification of MASLD cases

This first session in a two-part EASL DeepDive series on the 2024 EASL-EASD-EASO MASLD Clinical Practice Guidelines will provide a detailed examination of the recommendations concerning diagnosis, non-invasive assessment, and risk stratification, with a view to supporting evidence-based clinical practice.
Learning objectives
Have a good understanding of the concept/definition of MASLD within the framework of the new SLD nomenclature, including its contribution to disease progression in other diseases
Get familiar with the role of non-invasive tests for risk stratification in MASLD, their pro- and cons, and how and in whom to use them for screening/case finding
Get a detailed understanding of HCC risk and risk stratification in MASLD and the surveillance strategies to implement
This programme is part of the EASL Guidelines Implementation Programme on MASLD supported by Boehringer Ingelheim and Novo Nordisk. Boehringer Ingelheim and Novo Nordisk have had no input in the selection and creation of this programme.

EASL Studio Podcast: EASL CPGs on Vascular Liver Diseases: What’s New?

This episode addresses key challenges in vascular complications of liver disease, including the management of portal vein thrombosis (PVT) in patients with and without cirrhosis. Experts will explore controversies surrounding long-term anticoagulation therapy and discuss insights from the CIRROXABAN paper. Additionally, the episode will shed light on the management of splanchnic artery aneurysms, offering valuable guidance for clinical practice.
Moderator:  Pierre-Emmanuel Rautou
Faculty: Sarwa Darwish Murad, Juan-Carlos Garcia-Pagan, Valérie Vilgrain 
Related episodes
S4E11 – YI Choice: Gene therapy for liver disease — RNA interference and beyond
S4E6 – Regenerating the liver graft with a machine?
S3E11 – Regenerative Hepatology: From stem cells to tissue engineering
S2E9 – YI Choice: Propelling liver cell biology into the third dimension
All EASL Studio Podcasts are available on EASL Campus.
Click here to see all EASL Video Podcasts on Apple Podcasts.

EASL DeepDive: MASLD Cirrhosis: Addressing unmet needs and defining valuable endpoints

In this new edition of the EASL DeepDive, expert faculty guide participants through a focused and forward-looking discussion on key aspects of advanced MASLD, setting the stage for a deeper understanding of evolving clinical challenges and opportunities.
This EASL DeepDive webinar is supported by Boehringer Ingelheim. Boehringer Ingelheim has had no input into the content of this EASL DeepDive.Learning objectives
Understand the Pathophysiology: Describe the key pathophysiological mechanisms of MASLD and its progression to advanced liver disease and portal hypertension.
Identify Unmet Clinical Needs: Recognise the current gaps in diagnosis, management, and treatment of advanced MASLD, highlighting the challenges of healthcare professionals in clinical practice.
Evaluate Valuable Endpoints: Discuss the importance of selecting and utilising valuable clinical endpoints in managing MASLD to improve patient outcomes.
Explore Emerging Therapies: Review the latest therapeutic strategies and potential interventions for advanced MASLD, focusing on how they address the unmet needs in patient care.
All EASL DeepDive are available on EASL Campus.

EASL Studio Podcast: Steatotic Liver Disease Unpacked: Targeting Dynamic Risks

This EASL Studio episode explores state-of-the-art practices in diagnosing steatotic liver disease and stratifying patients effectively for targeted treatment in 2025. Focusing on integrating cardiometabolic risk profiling and dynamic alcohol consumption assessment, the discussion will discuss contemporary methods, frequency, and practical implementation in clinical settings to enhance precision medicine approaches.
Moderator: Aleksander Krag 
Faculty: Meena Bansal, Mattias Ekstedt, Arun Sanyal 
All EASL Studio Podcasts are available on EASL Campus.
Click here to see all EASL Video Podcasts on Apple Podcasts.

EASL Studio Podcast: Artificial Intelligence: Is This the Beginning of the End of the Medical Profession as We Know It?

Listen to this EASL Studio episode to explore how artificial intelligence (AI) is transforming healthcare. Discuss its potential to revolutionise medical practice, its limitations, and whether it poses a threat or an opportunity for the future of the medical profession.
Moderator: Ahmed Elsharkawy  
Faculty: Jakob Kather, Sabela Lens, Ashley Spann 
Related episodes:
EASL Studio at EASL Congress 2024 – Exploring new frontiers: The AI liver taskforce initiative
S4E5 – AI for dummies
S2E13 – Digital Pathology
All EASL Studio Podcasts are available on EASL Campus.
Click here to see all EASL Video Podcasts on Apple Podcasts.

EASL Studio Podcast: Rethinking Hepatitis B: Discussions with Patients – Adapting to Expanding Treatment Guidelines

With the release of the new HBV guidelines, treatment eligibility broadens. This EASL Studio explores how to communicate these changes, support shared decision-making, ensure adherence, and engage patients in ongoing care and clinical trials.
Moderator: Ahmed Elsharkawy 
Faculty: Markus Cornberg, Sital Shah, Thomas Tu, Su Wang
This EASL Studio is supported by Aligos Therapeutics and Gilead Sciences Europe Ltd . EASL has received no input from Aligos Therapeutics or Gilead Sciences Europe Ltd with regards to the content of this programme.
All EASL Studio Podcasts are available on EASL Campus.
Click here to see all EASL Video Podcasts on Apple Podcasts.